ATE323170T1 - Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann. - Google Patents
Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann.Info
- Publication number
- ATE323170T1 ATE323170T1 AT98907032T AT98907032T ATE323170T1 AT E323170 T1 ATE323170 T1 AT E323170T1 AT 98907032 T AT98907032 T AT 98907032T AT 98907032 T AT98907032 T AT 98907032T AT E323170 T1 ATE323170 T1 AT E323170T1
- Authority
- AT
- Austria
- Prior art keywords
- express
- binding protein
- protein gene
- chemokine
- smallpox virus
- Prior art date
Links
- 101710172503 Chemokine-binding protein Proteins 0.000 title abstract 2
- 241000700647 Variola virus Species 0.000 title 1
- 101150045588 A38L gene Proteins 0.000 abstract 3
- 101150091700 A41L gene Proteins 0.000 abstract 3
- 101100107503 Vaccinia virus (strain Western Reserve) VACWR166 gene Proteins 0.000 abstract 3
- 102000019034 Chemokines Human genes 0.000 abstract 2
- 108010012236 Chemokines Proteins 0.000 abstract 2
- 241000700618 Vaccinia virus Species 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102000027005 chemokine binding proteins Human genes 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9703592.7A GB9703592D0 (en) | 1997-02-21 | 1997-02-21 | Poxvirus chemokine-binding protein |
| GBGB9800113.4A GB9800113D0 (en) | 1998-01-05 | 1998-01-05 | A soluble vaccinia virus protein that binds chemokines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE323170T1 true ATE323170T1 (de) | 2006-04-15 |
Family
ID=26311039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98907032T ATE323170T1 (de) | 1997-02-21 | 1998-02-23 | Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann. |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US6355252B1 (https=) |
| EP (2) | EP0985046B1 (https=) |
| JP (1) | JP4191255B2 (https=) |
| AT (1) | ATE323170T1 (https=) |
| AU (1) | AU749921B2 (https=) |
| DE (1) | DE69834179T2 (https=) |
| WO (1) | WO1998037217A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE323170T1 (de) * | 1997-02-21 | 2006-04-15 | Oxxon Therapeutics Ltd | Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann. |
| GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| US20040241163A1 (en) * | 2001-04-05 | 2004-12-02 | Thomas Shenk | Compositions and methods for treating inflammation and related conditions |
| WO2003005953A2 (en) * | 2001-07-12 | 2003-01-23 | Immunex Corporation | Viral proteins capable of binding lar |
| GB0118532D0 (en) * | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| CA2460321A1 (en) * | 2001-09-20 | 2003-03-27 | Schering Corporation | Chemokines as adjuvants of immune response |
| AU2003259117A1 (en) * | 2002-07-10 | 2004-01-23 | The Regents Of The University Of California | Antimicrobial activity of interferon-inducible elr chemokines |
| KR20120002613A (ko) | 2002-08-12 | 2012-01-06 | 제네렉스, 인코포레이티드 | 폭스바이러스 및 암과 관련된 방법 및 조성물 |
| US20100189747A1 (en) * | 2003-07-31 | 2010-07-29 | Raymond Weinstein | Compositions and methods for treating or preventing hiv infection |
| US20050175627A1 (en) * | 2003-09-24 | 2005-08-11 | Oxxon Therapeutics Ltd. | HIV pharmaccines |
| WO2006076383A2 (en) * | 2005-01-11 | 2006-07-20 | Rosetta Stone Labs, Llc | Composition and method for inducing a protective vaccine response |
| US20070160571A1 (en) * | 2006-01-11 | 2007-07-12 | Mitchell Krathwohl | Composition and method for inducing protective vaccine response |
| KR101772375B1 (ko) * | 2005-09-07 | 2017-08-29 | 신라젠(주) | Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법 |
| US8980246B2 (en) | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
| WO2007041317A2 (en) * | 2005-09-29 | 2007-04-12 | Viral Logic Systems Technology Corp. | Immunomodulatory compositions and uses therefor |
| DK2005185T3 (da) | 2006-03-22 | 2011-01-31 | Viral Logic Systems Technology Corp | Fremgangsmåde til identifikation af polypeptidtargets |
| WO2008096359A2 (en) * | 2007-02-08 | 2008-08-14 | Rappaport Family Institute For Research In The Medical Sciences | Agents for the treatment of multiple sclerosis and methods of using same |
| KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| US8263064B2 (en) | 2007-06-04 | 2012-09-11 | Rappaport Family Institute For Research In The Medical Sciences | Method of suppressing disease severity of multiple sclerosis using chemokine CXC11 |
| WO2009082594A2 (en) * | 2007-11-26 | 2009-07-02 | Fox Chase Cancer Center | Secreted/cell bound poxvirus proteins and methods of use thereof as vaccines and anti-viral agents |
| WO2010103517A1 (en) | 2009-03-12 | 2010-09-16 | Rappaport Family Institute For Research In The Medical Sciences | Soluble compositions for the treatment of cxcr3-ligand associated diseases |
| ES2848650T3 (es) | 2009-09-14 | 2021-08-11 | Sillajen Biotherapeutics Inc | Terapia combinada contra el cáncer con virus vaccinia oncolítico |
| AU2012204467B2 (en) | 2011-01-04 | 2016-08-18 | Sillajen, Inc. | Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69628838T2 (de) * | 1995-04-19 | 2004-05-06 | The John P. Robarts Research Institute, London | Chemokin bindendes protein und verfahren zu seiner verwendung |
| US6140064A (en) | 1996-09-10 | 2000-10-31 | Theodor-Kocher Institute | Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3 |
| ATE323170T1 (de) * | 1997-02-21 | 2006-04-15 | Oxxon Therapeutics Ltd | Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann. |
| WO1998036766A1 (en) * | 1997-02-21 | 1998-08-27 | Isis Innovation Limited | Anti-hiv protein |
| JP2001168323A (ja) * | 1999-12-06 | 2001-06-22 | Mitsubishi Electric Corp | 半導体装置の製造方法 |
-
1998
- 1998-02-23 AT AT98907032T patent/ATE323170T1/de not_active IP Right Cessation
- 1998-02-23 EP EP98907032A patent/EP0985046B1/en not_active Expired - Lifetime
- 1998-02-23 US US09/367,781 patent/US6355252B1/en not_active Expired - Fee Related
- 1998-02-23 WO PCT/GB1998/000569 patent/WO1998037217A1/en not_active Ceased
- 1998-02-23 AU AU63020/98A patent/AU749921B2/en not_active Ceased
- 1998-02-23 EP EP20030022117 patent/EP1405916A1/en not_active Withdrawn
- 1998-02-23 DE DE69834179T patent/DE69834179T2/de not_active Expired - Fee Related
- 1998-02-23 JP JP53641598A patent/JP4191255B2/ja not_active Expired - Fee Related
-
2002
- 2002-01-15 US US10/047,761 patent/US20020071849A1/en not_active Abandoned
-
2004
- 2004-02-18 US US10/781,262 patent/US7384643B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP4191255B2 (ja) | 2008-12-03 |
| AU6302098A (en) | 1998-09-09 |
| US20040142002A1 (en) | 2004-07-22 |
| DE69834179T2 (de) | 2007-02-01 |
| EP0985046A1 (en) | 2000-03-15 |
| EP0985046B1 (en) | 2006-04-12 |
| US6355252B1 (en) | 2002-03-12 |
| WO1998037217A1 (en) | 1998-08-27 |
| JP2001513629A (ja) | 2001-09-04 |
| EP1405916A1 (en) | 2004-04-07 |
| DE69834179D1 (de) | 2006-05-24 |
| US20020071849A1 (en) | 2002-06-13 |
| AU749921B2 (en) | 2002-07-04 |
| US7384643B2 (en) | 2008-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE323170T1 (de) | Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann. | |
| FR2712603B1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
| FR2716893B1 (fr) | Virus recombinants, leur préparation et leur utilisation thérapeutique. | |
| DE3853088D1 (de) | Rekombinantes Avipoxvirus. | |
| FI951138A0 (fi) | Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa | |
| FI964592A0 (fi) | Papilloomavirusrokotteita | |
| KR970706806A (ko) | 신규한 아데노바이러스성 벡터, 패키징 세포주, 재조합 아데노바이러스와 그 방법(novel adenoviral vectors, packagning cell lines, recombinant adenoviruses and methods) | |
| DE3850019D1 (de) | Rekombinantes Avipoxvirus. | |
| ES2187527T3 (es) | Estructura de orden superior y enlace de acidos nucleicos peptidicos. | |
| ATE486614T1 (de) | Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie | |
| HUT77575A (hu) | Rekombináns adenovírus vektor és eljárás alkalmazására | |
| DE69032679D1 (de) | Threo (2R, 3S)-3-amino-2-hydroxypentansäure und threo (2R,3S)-3-(p-methoxy-benzyloxycarbonyl/FMOC) amino-2-hydroxy-pentansäure | |
| DE4090351T1 (de) | Rekombinantes Pockenvirus-Wirtsselektionssystem | |
| FI973309A0 (fi) | Menetelmä yhdistelmä-DNA-adenovirusgenomin valmistamiseksi | |
| FR2712602B1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
| AU4089899A (en) | Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy | |
| FR2724945B1 (fr) | Vecteurs viraux et utilisation en therapie genique | |
| EP0957936A4 (en) | COMPOSITIONS OF RECOMBINANT PAPILLOMAVIRUS VACCINES | |
| EP0227604A3 (en) | Use of oligopeptides in the treatment of viral infections | |
| FR2717495B1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
| FI971377L (fi) | Adenovirusperäisiä virusvektoreita, joissa on kaksi terapeuttista geeniä: itsemurha- ja immuunistimuloiva geeni | |
| FR2717496B1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
| AU2176997A (en) | Novel fused protein, gene therefor, recombinant vector, recombinant virus, and its use | |
| FR2717823B1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
| FR2717497B1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |